Related Experiment Video
Updated: Dec 30, 2025
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Genetic Testing in Prostate Cancer
Alexandra O Sokolova1,2,3, Heather H Cheng4,5
1Department of Medicine, University of Washington, Washington, USA.
Purpose Of Review:
This review summarizes recent advances in prostate cancer (PCa) genetics.
Recent Findings:
Upwards of 20% of metastatic castration-resistant prostate tumors (mCRPC) carry homologous recombination (HR) repair gene mutations, of which ~ 10% are germline (inherited). Another ~ 5% exhibit microsatellite instability (MSI-H) and/or mismatch repair deficiency (MMRd). Pembrolizumab is approved for tumors with MMRd, thus patients with mCRPC and MMRd are candidates for pembrolizumab. Emerging data indicate that platinum chemotherapy and poly ADP-ribose polymerase inhibitors (PARPi) are effective in PCa exhibiting HR deficiency. NCCN guidelines now recommend germline and somatic tumor testing in specific clinical scenarios due to treatment and family implications. Genetic testing in PCa patients may inform prognosis, treatment options, and have implications for family counseling. PARPi, platinum chemotherapy, and immune checkpoint inhibitors are promising targeted therapies for PCa with specific molecular features. Therapeutic advances, along with importance to relatives, are driving genetic testing in prostate cancer.
Insights
Genetic testing in prostate cancer (PCa) identifies mutations like homologous recombination repair (HR) and mismatch repair deficiency (MMRd). These findings guide targeted therapies such as PARPi and pembrolizumab, impacting treatment and family counseling.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Prostate cancer (PCa) is a significant health concern.
- Metastatic castration-resistant prostate cancer (mCRPC) presents therapeutic challenges.
- Understanding the genetic landscape of PCa is crucial for personalized medicine.
Purpose of the Study:
- To review recent advancements in prostate cancer genetics.
- To highlight the clinical relevance of genetic mutations in PCa.
- To discuss the implications of genetic testing for treatment and family counseling.
Main Methods:
- Literature review of recent studies on PCa genetics.
- Analysis of genetic mutation frequencies in mCRPC.
- Synthesis of data on targeted therapy efficacy based on molecular profiles.
Main Results:
- Over 20% of mCRPC tumors have homologous recombination (HR) repair gene mutations, with ~10% being germline.
- ~5% of mCRPC tumors exhibit microsatellite instability (MSI-H) and/or mismatch repair deficiency (MMRd).
- Pembrolizumab is approved for MMRd tumors; PARPi and platinum chemotherapy show efficacy in HR-deficient PCa.
Conclusions:
- Genetic testing in PCa patients provides prognostic information and identifies treatment options.
- Germline and somatic tumor testing are increasingly recommended in specific clinical scenarios.
- Targeted therapies like PARPi, platinum chemotherapy, and immune checkpoint inhibitors offer new hope for PCa patients with specific molecular features.
